Excellent
Fully Aligned
Patient Risk:
Low
Summary
The evaluated claim closely matches the provided FDA label text in sections 5.1 and 17, including the association with SYMTUZA discontinuation and the need for clinical/laboratory monitoring after stopping.
Category Scores
Accurate Statements
post-treatment acute exacerbation of hepatitis B in patients coinfected with HIV-1 and HBV can occur with discontinuation of SYMTUZA; patients should be monitored after stopping
Supported by Warnings and Precautions (5.1) and Patient Counseling (17), which state severe acute hepatitis B exacerbations may occur with discontinuation of SYMTUZA and require close clinical and laboratory follow-up for at least several months after stopping.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim accurately reflects the label warning regarding HIV-1/HBV coinfected patients discontinuing SYMTUZA and the recommended clinical/laboratory monitoring after stopping.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement